@@ -1,1 +1,1 @@ - +___<br> Axios Media is sold to Cox Enterprises<br> NEW YORK (AP) - Axios Media is being [https://www.behance.net/search/projects/?sort=appreciations&time=week&search=acquired acquired] by Cox Enterprises, which says it plans to push the online [https://www.bbcworldnewstoday.com/ BBC World News Today] provider into new markets while [https://www.dailymail.co.uk/home/search.html?sel=site&searchPhrase=broadening broadening] its coverage. Axios, citing sources, reported Monday that the deal is worth $525 million. Cox, a conglomerate whose other media companies include The Atlanta Journal-Constitution and Dayton Daily News, first became an investor in Axios last year. Axios co-founders and former Politico journalists Jim VandeHei, Mike Allen and Roy Schwartz will continue to hold substantial stakes in the company and will lead editorial and day-to-day business decisions.<br> ___<br> Wall Street end flat as investors await inflation updates<br> NEW YORK (AP) - Stocks closed flat on Wall Street as investors prepare for a busy week of updates on inflation.<br><br>The S&P 500 gave up early gains and closed down 0.1% Monday, while the Dow Jones [https://www.britannica.com/search?query=Industrial%20Average Industrial Average] edged higher and the Nasdaq fell slightly. Small-company stocks outpaced the broader market in a sign of investors´ confidence in the economy. Retailers and communications stocks were among the biggest winners. Clean energy companies, including First Solar, rose following Senate approval of Democrats´ big election-year economic package.<br><br>The government will release its July reports for consumer prices and wholesale prices later this week.<br> ___<br> Pfizer buying spree continues with $5.4B hematology deal<br> NEW YORK (AP) [https://www.blogrollcenter.com/?s=-%20Pfizer - Pfizer] is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its [https://www.cbsnews.com/search/?q=revenue%20soared revenue soared] during the pandemic. Pfizer said Monday that its latest acquisition will boost its work in rare hematology.<br><br>Global Therapeutics produces Oxybryta tablets for treating sickle cell disease. Pfizer has been flush with cash since its COVID-19 vaccine, Comirnaty, and treatment, Paxlovid, have hit the market.